**Poly-substance use, treatment completion, and contact with the justice system: a multistate analysis of treatments for substance use disorders between 2010-2019 in Chile**

# Background

Substance use disorders (SUD) are related to criminality, such as violence1, arrests2 and reincarceration3. People with SUD also tend to use more than one substance4 during active use in their lifetime5. People with polysubstance use (PSU) are considered a high-risk population not only due to its association with mortality6, relapse7 and other detrimental outcomes6,8,9, but also because of its high prevalence among people in contact with the criminal justice system (CJS)10,11. Importantly, the mediating role of treatment completion on the link between PSU and contact with CJS remains unclear.

Completing SUD treatment is associated with better outcomes, including contact with CJS12–15. Although PSU has been used to predict contact with CJS16–18, the evidence regarding its role in treatment outcomes is mixed. Some studies report a lower likelihood of treatment completion among people with PSU19–21, while others found no association22 or higher completion rates23. Thus, it is crucial to determine the role of treatment completion in order to improve outcomes in people with PSU.

The relationship between people with PSU, treatment completion, and contact with CJS can be affected by factors such as treatment goals, patient characteristics, resource availability, and SUD severity profiles which are highly contingent on treatment settings24–26. Thus, analyses must account for differences in treatment settings.

Additionally, studying the role of treatment outcomes is challenging due to limited research on people with PSU in Latin America27. Furthermore, like many studies in the global north, high-risk populations have often been overlooked28. An analysis of data from studies conducted in six Latin American countries found that 21% of participants were people with PSU, and males, people aged 18-34 from Chile, Uruguay, and Argentina, were more likely to report PSU28. Similarly, studies conducted in Chilean hard-to-reach populations have associated PSU with school dropout, unemployment, sexual risk, and antisocial behaviors29–31.

Although the relationship between SUD and contact with CJS is documented in the global north32, little is known about the effect of treatment outcomes among people with PSU in other contexts. This study aims to estimate the mediating effects of completing SUD treatment on the link between PSU and contact with CJS among adult patients admitted to SUD treatment programs in Chile during 2010-2019. Understanding this relationship could inform effective prevention and intervention strategies for PSU and provide insight into the effectiveness of SUD treatment in reducing the risk of contact with CJS among individuals with baseline PSU in Chile. This study contributes to a growing literature on the importance of addressing longitudinal dynamics in specific profiles of SUD patients.

# Research questions, aims, and hypothesis

* **Research question:** What are the mediating effects of completing SUD treatment on the relationship between baseline PSU and contact with CJS in Chile in the short (six months), middle (1 year), and long term (3 years)?
* **Aims:** Estimate the mediating effects of completing SUD treatment on the relationship between PSU at admission and contact with CJS among adult patients admitted to SUD treatment programs in Chile during 2010-2019. Specific: (1) To describe the prevalence of PSU, treatment completion, and contact with CJS in the sample, (2) to compare the risk of contact with CJS between people with poly and single-substance use, and (3) to estimate the proportion of the effect of PSU and treatment outcome on the contact with CJS.
* **Hypothesis:** Baseline PSU is related to lower treatment completion rates (1), baseline PSU is linked to a greater risk of contact with CJS (2), patients with PSU will have a differential risk of contact with CJS associated with treatment completion, and treatment completion will explain part of the relationship between PSU and contact with CJS (3).

# Methodology

This research design is a retrospective cohort based on the administrative data's record linkage. The study will use data from Chilean SUTs programs and Prosecutor’s Office through a deterministic linkage process. We will request an amendment to an existing ethical approval from a study using the same data. The exposure variable will be the baseline PSU (using more than one main substance among alcohol and illicit drugs at admission to SUD treatment, whether sequential or concurrent)33,34, the mediator variable will be SUD treatment outcome (complete vs. dropout or spelled by misconduct), and the outcome will be contact with CJS (offense that led to a condemnatory sentence). The study will control for various confounding variables related to substance use, demographics, and social factors through weights generated through the inverse probability of PSU27. We will use the illness-death multistate model to simultaneously estimate transitions between admission and treatment outcome, treatment outcome and contact with CJS, and admission and contact with CJS (without completing treatment). We will then calculate the Aalen-Johansen estimator for transition probabilities at 6 months, 1 and 3 years35. Secondary analyses will focus on mediation, estimating the effects of PSU given treatment outcome at 6 months, 1 and 3 years using a standard time-to-first-event approach. Proportions mediated will be estimated using the bootstrap method. We also plan to run separate analyses in patients admitted to different treatment settings. Preliminary markdowns are available at bit.ly/3w9wygJ.

# Project milestones

* **Progress report:** It will include: a theoretical framework and descriptive analyses exploring the connections between PSU, SUT outcome, and contact with CJS.
* **Paper:** Sent to a Substance Abuse, Criminology or Public Health international journal before month 12 of the study.
* **Presentation in Scientific meetings:** Our goal is to present this study at least at one international conference, such as the Society for Epidemiologic Research or similar, and in possible scientific community activities organized by Universidad de Chile or other national institutions.

# Research team

Our research team has experience in public health and criminology and skills in using large datasets in substance use epidemiology, program and policy evaluation, and treatment research (See Table 1). Previously, part of the team collaborated on SUT policy analysis publications.

**Table 1. Research team.**

|  |  |  |  |
| --- | --- | --- | --- |
| Name | Role | Expertise | Time spent |
| Andrés González | P.I. | Ph.D. student (School of Public Health, Universidad de Chile). He has worked as technical staff in research related to occupational health and SUD treatments. He has been working on the Treatment patients dataset since 2019, collaborating with Dr. Castillo-Carniglia o several papers | *6 hours per week* |
| José Ruiz-Tagle | Co-I | Ph.D. student (Public Policy, Universidad Mayor). He has worked on research projects related to substance use treatments. He also has been working on the dataset on Treatment patients since 2019 along with Dr. Castillo-Carniglia. He collaborated in the analysis of several papers linked to SUD. | *3 hours per week* |
| Mariel Mateo | Co-I | Ph.D. student (School of Criminology and Criminal Justice, Griffith University, Australia). She coordinated the first Outcome Study of Substance Use Treatment in Chile and led the Drug research area in the Justice and Society Studies Centre (Pontificia Universidad Católica) between 2015 and 2019. | *2 hours per week* |
| *Álvaro Castillo-Carniglia* | Sup | Ph.D., Associate professor, and Director of the Ph.D. Programme in Public Policy, Universidad Mayor. He has a background in epidemiology, and his main research areas are the measurement of SUDs in the population. He has co-directed several theses in public health related to treatment dropouts and readmissions. | *2 hours fortnight* |
| *Note: P.I.: Principal Investigator; Co-I: Co-Investigator; Sup.: Supervisor.* | | | |

# Timeline

Based on the work carried out in the 2022 intramural fund, we will delve into the transformation and processing of data following a longitudinal perspective of nested events by subjects. Additionally, a significant amount of time will be devoted to discussing and implementing knowledge of causal inference involved in the analysis. The process is summarized in Figure 1.

**Figure 1. Gantt chart of activities involved in research progress.**

Imagen que contiene Tabla

Descripción generada automáticamente

# Budget

Funds will be used to cover expenses for attending international conferences and a virtual computer (e.g., an annual subscription to DataCamp Teams). The cost of attending international conferences is between 2,000-4,000 USD36. Thus, the funds should cover a great portion of these expenses. Also, it can be used for workshops, manuscript editing (if needed), and as an incentive for the researchers.

# References

1. Duke AA, Smith KMZ, Oberleitner LMS, Westphal A, McKee SA. Alcohol, drugs, and violence: A meta-meta-analysis. *Psychol Violence*. 2018;8(2):238-249. doi:10.1037/vio0000106

2. Sugie NF, Turney K. Beyond Incarceration: Criminal Justice Contact and Mental Health. *Am Sociol Rev*. 2017;82(4):719-743. doi:10.1177/0003122417713188

3. Thomas EG, Spittal MJ, Taxman FS, Puljević C, Heffernan EB, Kinner SA. Association between contact with mental health and substance use services and reincarceration after release from prison. *PLoS One*. 2022;17(9):e0272870. doi:10.1371/journal.pone.0272870

4. Liu Y, Williamson V, Setlow B, Cottler LB, Knackstedt LA. The importance of considering polysubstance use: lessons from cocaine research. *Drug Alcohol Depend*. 2018;192:16-28. doi:10.1016/j.drugalcdep.2018.07.025

5. Connor JP, Gullo MJ, White A, Kelly AB. Polysubstance use. *Curr Opin Psychiatry*. 2014;27(4):269-275. doi:10.1097/YCO.0000000000000069

6. Gjersing L, Bretteville-Jensen AL. Patterns of substance use and mortality risk in a cohort of ‘hard-to-reach’ polysubstance users. *Addiction*. 2018;113(4):729-739. doi:10.1111/add.14053

7. Hassan AN, Le Foll B. Polydrug use disorders in individuals with opioid use disorder. *Drug Alcohol Depend*. 2019;198:28-33. doi:10.1016/j.drugalcdep.2019.01.031

8. Wang L, Min JE, Krebs E, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. *International Journal of Drug Policy*. 2017;49:32-40. doi:10.1016/j.drugpo.2017.07.009

9. Quek LH, Chan GCK, White A, et al. Concurrent and Simultaneous Polydrug Use: Latent Class Analysis of an Australian Nationally Representative Sample of Young Adults. *Front Public Health*. 2013;1. doi:10.3389/fpubh.2013.00061

10. Ford JA, Ortiz K, Schepis TS, McCabe SE. Types of criminal legal system exposure and polysubstance use: Prevalence and correlates among U.S. adults in the National Survey on Drug Use and Health, 2015–2019. *Drug Alcohol Depend*. 2022;237:109511. doi:10.1016/j.drugalcdep.2022.109511

11. Skjaervø I, Skurtveit S, Clausen T, Bukten A. Substance use pattern, self-control and social network are associated with crime in a substance-using population. *Drug Alcohol Rev*. 2017;36(2):245-252. doi:10.1111/dar.12406

12. White W. Recovery/remission from substance use disorders: an analysis of reported outcomes in 415 scientific reports, 1868–2011. 2012. Philadelphia Department of Behavioral Health and Intellectual disAbility Services and the Great Lakes Addiction Technology Transfer Center: Chicago, Illinois & Philadelphia, PA. Accessed March 13, 2023. https://www.naadac.org/assets/2416/whitewl2012\_recoveryremission\_from\_substance\_abuse\_disorders.pdf

13. Andersson HW, Wenaas M, Nordfjærn T. Relapse after inpatient substance use treatment: A prospective cohort study among users of illicit substances. *Addictive Behaviors*. 2019;90:222-228. doi:10.1016/j.addbeh.2018.11.008

14. Rezai-Zadeh KP, Engstrom RN, Sharma A, et al. Generational trends and patterns in readmission within a statewide cohort of clients receiving heroin use disorder treatment in Maryland, 2007–2013. *J Subst Abuse Treat*. 2019;96:82-91. doi:https://doi.org/10.1016/j.jsat.2018.10.010

15. Timko C, Nash A, Owens MD, Taylor E, Finlay AK. Systematic Review of Criminal and Legal Involvement After Substance Use and Mental Health Treatment Among Veterans: Building Toward Needed Research. *Subst Abuse*. 2020;14:117822181990128. doi:10.1177/1178221819901281

16. Carbonneau R, Vitaro F, Brendgen M, Tremblay RE. Longitudinal patterns of polysubstance use throughout adolescence: association with adult substance use and psychosocial outcomes controlling for preadolescent risk factors in a male cohort. *Soc Psychiatry Psychiatr Epidemiol*. Published online March 7, 2023. doi:10.1007/s00127-023-02454-8

17. Lammers SMM, Soe-Agnie SE, de Haan HA, Bakkum GAM, Pomp ER, Nijman HJM. [Substance use and criminality: a review]. *Tijdschr Psychiatr*. 2014;56(1):32-39.

18. Beaudoin M, Potvin S, Dellazizzo L, Luigi M, Giguère CE, Dumais A. Trajectories of Dynamic Risk Factors as Predictors of Violence and Criminality in Patients Discharged From Mental Health Services: A Longitudinal Study Using Growth Mixture Modeling. *Front Psychiatry*. 2019;10. doi:10.3389/fpsyt.2019.00301

19. Levola J, Aranko A, Pitkänen T. Psychosocial difficulties and treatment retention in inpatient detoxification programmes. *Nordic Studies on Alcohol and Drugs*. 2021;38(5):434-449. doi:10.1177/14550725211021263

20. Choi NG, DiNitto DM. Older-Adult Marijuana Users in Substance Use Treatment: Characteristics Associated with Treatment Completion. *J Psychoactive Drugs*. 2020;52(3):218-227. doi:10.1080/02791072.2020.1745966

21. Andersson HW, Lauvsnes ADF, Nordfjærn T. Emerging Adults in Inpatient Substance Use Treatment: A Prospective Cohort Study of Patient Characteristics and Treatment Outcomes. *Eur Addict Res*. 2021;27(3):206-215. doi:10.1159/000512156

22. Andersson HW, Steinsbekk A, Walderhaug E, Otterholt E, Nordfjærn T. Predictors of Dropout From Inpatient Substance Use Treatment: A Prospective Cohort Study. *Subst Abuse*. 2018;12:117822181876055. doi:10.1177/1178221818760551

23. Basu D, Ghosh A, Sarkar S, Patra BN, Subodh BN, Mattoo SK. Initial treatment dropout in patients with substance use disorders attending a tertiary care de-addiction centre in north India. *Indian J Med Res*. 2017;146(Supplement):S77-S84. doi:10.4103/ijmr.IJMR\_1309\_15

24. Reif S, Stewart MT, Torres ME, Davis MT, Dana BM, Ritter GA. Effectiveness of value-based purchasing for substance use treatment engagement and retention. *J Subst Abuse Treat*. 2021;122:108217. doi:10.1016/j.jsat.2020.108217

25. Tiet QQ, Ilgen MA, Byrnes HF, Harris AHS, Finney JW. Treatment setting and baseline substance use severity interact to predict patients’ outcomes. *Addiction*. 2007;102(3):432-440. doi:10.1111/j.1360-0443.2006.01717.x

26. Fiestas F, Ponce J. Eficacia de las comunidades terapéuticas en el tratamiento de problemas por uso de sustancias psicoactivas: una revisión sistemática. *Rev Peru Med Exp Salud Publica*. 2012;29(1):12-20. https://www.redalyc.org/articulo.oa?id=36323255003

27. Lalwani K, Whitehorne-Smith P, Walcott G, McLeary JG, Mitchell G, Abel W. Prevalence and sociodemographic factors associated with polysubstance use: analysis of a population-based survey in Jamaica. *BMC Psychiatry*. 2022;22(1):513. doi:10.1186/s12888-022-04160-2

28. Reyes JC, Perez CM, Colon HM, Dowell MH, Cumsille F. Prevalence and Patterns of Polydrug Use in Latin America: Analysis of Population-based Surveys in Six Countries. *Rev Eur Stud*. 2013;5(1). doi:10.5539/res.v5n1p10

29. Santis B R, Hidalgo C CG, Hayden C V, et al. Consumo de sustancias y conductas de riesgo en consumidores de pasta base de cacaína no consultantes a servicios de rehabilitación. *Rev Med Chil*. 2007;135(1). doi:10.4067/S0034-98872007000100007

30. Olivari CF, Gaete J, Rodriguez N, et al. Polydrug Use and Co-occurring Substance Use Disorders in a Respondent Driven Sampling of Cocaine Base Paste Users in Santiago, Chile. *J Psychoactive Drugs*. 2022;54(4):348-357. doi:10.1080/02791072.2021.1976886

31. Vilugrón F, Molina G. T, Gras-Pérez ME, Font-Mayolas S. Precocidad de inicio del consumo de sustancias psicoactivas y su relación con otros comportamientos de riesgo para la salud en adolescentes chilenos. *Rev Med Chil*. 2022;150(5):584-596. doi:10.4067/s0034-98872022000500584

32. Holloway KR, Bennett TH, Farrington DP. The effectiveness of drug treatment programs in reducing criminal behavior: a meta-analysis. *Psicothema*. 2006;18(3):620-629.

33. Font-Mayolas S, Calvo F. Polydrug Definition and Assessment: The State of the Art. *Int J Environ Res Public Health*. 2022;19(20):13542. doi:10.3390/ijerph192013542

34. Crummy EA, O’Neal TJ, Baskin BM, Ferguson SM. One Is Not Enough: Understanding and Modeling Polysubstance Use. *Front Neurosci*. 2020;14. doi:10.3389/fnins.2020.00569

35. Crowther MJ, Lambert P. MULTISTATE: Stata module to perform multi-state survival analysis. Published online January 18, 2023. https://EconPapers.repec.org/RePEc:boc:bocode:s458207

36. Sarabipour S, Khan A, Seah S, et al. Evaluating features of scientific conferences: A call for improvements. Published online 2020. doi:10.1101/2020.04.02.022079